News | April 30, 2026
RPG Life Sciences reports Rs 707.5 crore revenue in FY26, 8% annual growth
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
Former Novo Nordisk and Pharmanovia executive to lead next growth phase in NAD diagnostics and personalised health innovation
The figures highlight double-digit revenue growth, margin expansion, and continued momentum in complex generics and peptides CDMO platform
The product is manufactured at AKUMS’ state-of-the-art injectable facility in Kotdwar, Uttarakhand
The company achieved 20% EBITDA profitability in Bengaluru and reached operational profitability across all its active cities
The company reported consolidated total income of Rs. 161.3 crore in Q4 FY26, a strong jump from Rs. 120.3 crore in the same period last year
Rs. 40 cr buyback, 200% dividend announced
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
New appointments bring diagnostics and medtech expertise to strengthen healthcare delivery and policy engagement
The webinar series will showcase next-gen imaging technologies, global expert insights, and hands-on sessions on microscopy innovations
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
